May 2026
📣 VC round data is live. Check it out!
Largest Biopharmaceuticals Public Companies in Poland
Benchmark revenue and EBITDA valuation multiples for public comps like
Celon Pharma, Bioceltix, Captor Therapeutics, Ryvu Therapeutics and Bioton.
 | Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder. | $6 | -4% | $309M | $324M | 6.6x | 78.7x | ||
| Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis. | $22 | -21% | $123M | $104M | — | (26.3x) | ||
| Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options. | $21 | +137% | $118M | $109M | 25.1x | (12.1x) | ||
| Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways. | $5 | -40% | $112M | $111M | 4.8x | (5.0x) | ||
| Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland. | $1 | +5% | $102M | $116M | 1.5x | 8.2x | ||
| Synthaverse SA is a global pharmaceutical company. Its goal is to provide the best, innovative and unique solutions for medicine. Its work is based on scientific and health knowledge. Along with its expert approach, it allows the company to create reliable and unique products. It manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer. | $1 | -42% | $61M | $84M | 7.2x | (398.6x) | ||
| Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis. | $2 | -22% | $33M | $34M | 7.9x | (2.4x) | ||
| Poltreg SA is a biotechnology company at the clinical stage developing an innovative generation of medicines using T-regulatory cells (TREGS) in the treatment of autoimmune diseases. | $5 | -42% | $32M | $32M | — | (9.6x) | ||
| Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs. | $1 | -19% | $30M | $26M | — | (3.4x) | ||
| Nanogroup SA develops biotechnological and medical projects for diagnostics, therapy and rehabilitation of oncological patients. | $1 | -10% | $27M | $24M | 41128.6x | (16.7x) | ||
| Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions. | $5 | -40% | $12M | $17M | 0.5x | 4.5x | ||
| Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy. | $0 | +69% | $9M | $9M | 264.2x | (147.6x) | ||
| Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects. | $1 | -35% | $6M | $10M | — | (3.3x) | ||
| Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel. | $2 | 0% | $5M | $4M | 6.9x | (14.6x) | ||
| Cannabis Poland SA is engaged in the business of cannabis, wherein it supplies plant products containing cannabinoids for pharmaceutical industry. | $0 | -38% | $3M | $3M | 45.3x | (4.4x) | ||
| Median | $2 | -21% | $32M | $32M | 7.2x | (5.0x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.